When starting GLP-1 RAs, these findings suggest the need for individualized medicine strategies, which may include careful patient selection, risk-benefit analyses, and possibly introducing earlier or more frequent colorectal cancer screening for high-risk patients. This evidence concerns the gene GLP1R and colorectal cancer.